# AbbVie-Backed ADARx Plans IPO to Fund siRNA Clinical Trials

ADARx Pharmaceuticals has renewed its plans to go public, seeking to raise capital for ongoing clinical trials of its small interfering RNA (siRNA) medicines. The biotech company is backed by AbbVie and aims to advance a pipeline of next-generation siRNA therapies currently in clinical development.

The company’s decision to pursue an initial public offering comes as it looks to fund multiple clinical-stage programs. ADARx is developing siRNA-based treatments that target disease-causing genes at the RNA level, a therapeutic approach that has gained traction in recent years for its potential to address many conditions.

ADARx’s IPO plans represent a renewed push for public market financing after earlier attempts. The company has not disclosed specific financial terms or a timeline for the offering.

## Context

siRNA therapeutics represent a growing area of drug development in the life sciences. These medicines work by silencing specific genes that contribute to disease, offering a precision approach for conditions where traditional small-molecule drugs or biologics may be less effective. Major pharmaceutical companies, including AbbVie through its partnership with ADARx, have invested in this technology platform. Successful IPO funding could support the expansion of clinical trials for siRNA-based candidates, potentially advancing new treatment options in areas such as rare genetic diseases, metabolic disorders, and other therapeutic fields that rely on gene-silencing mechanisms.

Source: [original report](https://www.fiercebiotech.com/biotech/abbvie-backed-adarx-plans-ipo-fund-array-clinical-stage-sirna-therapies)